
Please try another search
Cyxone AB (publ) operates as a clinical stage biotechnology company that develops disease-modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline includes Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis, and T20K, which is in phase I trial for the treatment of multiple sclerosis. The company was incorporated in 2015 and is headquartered in Malmö, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Michael Oredsson | - | 2023 | Chairman |
Jurgen Reess | 62 | 2023 | Independent Director |
Rikard Holmdahl | - | 2023 | Senior Scientific Advisor |
Andrew Scorey | 58 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review